Pramipexole - Revision history

MDElliottMD: parser-claude: Pramipexole MedTemplate refill, Top 300 stub upgrade

2026-05-23T07:18:46Z

parser-claude: Pramipexole MedTemplate refill, Top 300 stub upgrade

← Older revision		Revision as of 07:18, 23 May 2026
Line 1:		Line 1:
	{{MedTemplate		{{MedTemplate
	\| generic = Pramipexole		\| generic = Pramipexole
	\| brand = Mirapex		\| brand = Mirapex (IR), Mirapex ER
	\| structure =		\| structure =
	\| classes = ~~Antiparkinsonian,~~ Dopamine ~~agonist~~		\| classes = [[:Category:Dopamine agonists\|Dopamine D2/D3 receptor agonist (non-ergot)]], [[:Category:Antiparkinsonians\|Antiparkinsonian]]
	\| ~~mechanism =~~ D2/D3 receptor agonist		\| uses = <vote slug="parkinson-disease-monotherapy-use">Parkinson disease, early monotherapy (FDA)</vote>, <vote slug="parkinson-disease-adjunct-use">Parkinson disease, advanced as adjunct to levodopa (FDA)</vote>, <vote slug="restless-legs-syndrome-use">Restless legs syndrome (FDA)</vote>, <vote slug="bipolar-depression-use">Bipolar depression (off-label, modest evidence)</vote>
	\| uses =		\| starting_dose = Parkinson disease: 0.125 mg PO TID, titrate weekly to maintenance ~1.5 mg TID. Restless legs syndrome: 0.125 mg PO 2-3 hours before bedtime, titrate to 0.5 mg/day if needed
	\| starting_dose =		\| preparations = IR tablets 0.125, 0.25, 0.5, 0.75, 1, 1.5 mg; ER tablets 0.375, 0.75, 1.5, 2.25, 3, 3.75, 4.5 mg
	\| preparations =		\| fda_max = 4.5 mg/day (Parkinson disease); 0.5 mg/day (restless legs syndrome)
	\| fda_max =		\| pill_id =
	\| routes =		\| routes = Oral
	\| onset =		\| onset = Motor improvement over days at therapeutic dose
	\| duration =		\| duration = TID dosing (IR); once-daily (ER)
	\| halflife =		\| halflife = 8-12 hours (longer in elderly and renal impairment)<ref name="mirapex-label">FDA Prescribing Information, Mirapex (pramipexole dihydrochloride), Boehringer Ingelheim, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020667s019,021514s007lbl.pdf</ref>
	~~\| bioavailability =~~		\| bioavailability = >90% (oral)<ref name="mirapex-label" />
	~~\| pregnancy~~ =		\| pregnancy = Limited human data; rarely indicated in pregnancy given the typical patient population.{{citation needed}}
	~~\| legal~~ =		\| legal = [[USLegal:Prescription only\|Rx-only]] in US
	\| ~~intro =~~		\| mechanism = <vote slug="pramipexole-mech-claim">Selective non-ergot D2 and D3 dopamine receptor agonist with preference for the D3 subtype. In Parkinson disease, monotherapy use early in the course delays the need for levodopa; adjunct use later in the course extends "on" time and allows levodopa dose reduction. The D3-preference is the proposed mechanism for the off-label efficacy in bipolar depression and treatment-resistant depression.</vote> '''Impulse control disorders''' (pathological gambling, hypersexuality, compulsive shopping, binge eating) are a recognized class effect of dopamine agonists with substantially higher incidence than with levodopa. Other major adverse effects include somnolence with sleep attacks (potentially while driving), hallucinations, peripheral edema, and dyskinesias. Renally eliminated; dose adjustment required in renal impairment<ref name="mirapex-label" />.
	~~\| pharmacokinetics~~ =
	~~\| pharmacodynamics~~ =
	\| ~~indications~~ =
	\| ~~dosing~~ =
	\| ~~effects~~ =
	~~\| interactions~~ = <~~pharmaInteractions~~/>
	~~\| pregnancy_details =~~
	~~\| monitoring =~~
	~~\| counseling =~~
	~~\| anecdotes =~~
	~~\| seealso =~~
	~~\| references~~ =
	}}		}}

			== References ==
			<references />

	[[Category:~~Antiparkinsonism agents~~]]		[[Category:Dopamine agonists]]
	[[Category:~~Antiparkinsonian]]~~		[[Category:Antiparkinsonians]]
	~~[[Category:Dopamine Agonists~~]]

MDElliottMD: Category taxonomy ship: retag Antiparkinsonian Medicines -> Antiparkinsonism agents

2026-05-22T00:37:18Z

Category taxonomy ship: retag Antiparkinsonian Medicines -> Antiparkinsonism agents

← Older revision		Revision as of 00:37, 22 May 2026
Line 32:		Line 32:


	[[Category:~~Antiparkinsonian Medicines~~]]		[[Category:Antiparkinsonism agents]]
	[[Category:Antiparkinsonian]]		[[Category:Antiparkinsonian]]
	[[Category:Dopamine Agonists]]		[[Category:Dopamine Agonists]]

MDElliottMD: Comprehensive categorization: +Dopamine Agonists

2026-05-15T18:42:21Z

Comprehensive categorization: +Dopamine Agonists

← Older revision		Revision as of 18:42, 15 May 2026
Line 34:		Line 34:
	[[Category:Antiparkinsonian Medicines]]		[[Category:Antiparkinsonian Medicines]]
	[[Category:Antiparkinsonian]]		[[Category:Antiparkinsonian]]
			[[Category:Dopamine Agonists]]

MediaWiki default: Assign pharmacological categories from List_of_CNS-active_medicines

2026-05-14T15:07:04Z

Assign pharmacological categories from List_of_CNS-active_medicines

← Older revision		Revision as of 15:07, 14 May 2026
Line 31:		Line 31:
	}}		}}


			[[Category:Antiparkinsonian Medicines]]
	[[Category:Antiparkinsonian]]		[[Category:Antiparkinsonian]]

MDElliottMD: Pharmacopedia: add

2026-05-14T03:31:06Z

Pharmacopedia: add <pharmaInteractions/>

← Older revision		Revision as of 03:31, 14 May 2026
Line 22:		Line 22:
	\| dosing =		\| dosing =
	\| effects =		\| effects =
	\| interactions =		\| interactions = <pharmaInteractions/>
	\| pregnancy_details =		\| pregnancy_details =
	\| monitoring =		\| monitoring =

MDElliottMD: Pharmacopedia: remove contraindications parameter

2026-05-14T02:40:47Z

Pharmacopedia: remove contraindications parameter

← Older revision		Revision as of 02:40, 14 May 2026
Line 22:		Line 22:
	\| dosing =		\| dosing =
	\| effects =		\| effects =
	~~\| contraindications =~~
	\| interactions =		\| interactions =
	\| pregnancy_details =		\| pregnancy_details =

MDElliottMD: Added empty fda_max parameter to MedTemplate call

2026-05-13T02:32:52Z

Added empty fda_max parameter to MedTemplate call

← Older revision		Revision as of 02:32, 13 May 2026
Line 8:		Line 8:
	\| starting_dose =		\| starting_dose =
	\| preparations =		\| preparations =
			\| fda_max =
	\| routes =		\| routes =
	\| onset =		\| onset =
Line 32:		Line 33:

	[[Category:Antiparkinsonian]]		[[Category:Antiparkinsonian]]

MDElliottMD: Expand stub to full MedTemplate parameter set

2026-05-13T01:00:00Z

Expand stub to full MedTemplate parameter set

@@ Line 1: / Line 1: @@
 {{MedTemplate
-| generic           = Pramipexole
+| generic            = Pramipexole
-| brand             = Mirapex
+| brand              = Mirapex
-| classes           = Antiparkinsonian, Dopamine agonist
+| structure          =
-| mechanism         = D2/D3 receptor agonist
+| classes            = Antiparkinsonian, Dopamine agonist
 }}
 [[Category:Antiparkinsonian]]

MDElliottMD: Auto-created stub

2026-05-13T00:00:00Z

Auto-created stub

New page

{{MedTemplate
| generic = Pramipexole
| brand = Mirapex
| classes = Antiparkinsonian, Dopamine agonist
| mechanism = D2/D3 receptor agonist
}}
[[Category:Antiparkinsonian]]